Why the study?
Trial design and safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation for symptomatic atrial fibrillation require reexamination to provide meaningful data for regulatory decision-making.
This AFA-ARC consensus document provides updated standards for trial design and endpoints in pivotal clinical trials evaluating catheter ablation for atrial fibrillation to support regulatory decision-making.
Answers are grounded in this paper and cite their sources.
Updates AF ablation trial endpoints and designs for regulatory use; extends prior consensus across paroxysmal to longstanding persistent populations.
The aim of the AFA-ARC (Atrial Fibrillation Ablation Academic Research Consortium) initiative is to reexamine trial design and the safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation for the treatment of symptomatic atrial fibrillation to provide meaningful and interpretable data to support regulatory decision-making. Beginning in July 2024, a group of international experts began meeting regularly both virtually together and separately in working groups (group 1 effectiveness end points; group 2 safety end points; and group 3 trial design and report forms), with one in-person meeting held in April 2025, and revisions of draft proposals from January 2025 to February 2026. The Food and Drug Administration Office of Cardiovascular Devices at the Center for Devices and Radiological Health provided input throughout the revision and proposal process. A patient advocate participated in the in-person meeting and during the revision phase. Heart Rhythm Society leadership was involved throughout the process and in the revision phase. Industry representatives were sent drafts of the proposed manuscripts during the revision phase before submission. The result of this process was the creation of a combined document to reexamine trial design and the safety and effectiveness end points for pivotal clinical trials evaluating catheter ablation of atrial fibrillation. This document represents contributions from each of the 3 Working Groups. The Heart Rhythm Society endorsed this document. This AFA-ARC document proposes revised effectiveness and safety end points, study design, and report forms for studies evaluating AF ablation in patients with symptomatic paroxysmal, persistent, or longstanding persistent AF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a review in Symptomatic paroxysmal, persistent, or longstanding persistent atrial fibrillation. Catheter ablation was evaluated on Revised effectiveness and safety end points, study design, and report forms. The AFA-ARC initiative proposed revised effectiveness and safety end points, study design, and report forms for pivotal clinical trials evaluating catheter ablation of atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: